Related Experiment Video
Updated: Oct 15, 2025
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.0K
Visual functional changes after ocriplasmin injection for vitreomacular traction: A microperimetric analysis.
Claudio Furino1, Alfredo Niro2, Luigi Sborgia1
1Department of Medical Science, Neuroscience and Sense Organs, Eye Clinic, University of Bari, Bari, Italy.
Taiwan Journal of Ophthalmology
|October 27, 2021
Summary
Ocriplasmin injection for vitreomacular traction (VMT) causes temporary vision impairment, which resolves by 3 months. Functional recovery is better in patients with VMT release.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Vitreomacular traction (VMT) affects vision by distorting the macula.
- Ocriplasmin is an enzymatic treatment for VMT.
Purpose of the Study:
- To evaluate functional changes after ocriplasmin injection for VMT using microperimetry.
- To compare functional outcomes based on VMT release.
Main Methods:
- Prospective study of patients receiving intravitreal ocriplasmin.
- Microperimetry, OCT, and BCVA assessed at baseline, 1 week, 1 month, and 3 months.
- Analysis of functional parameters in patients with (Group A) and without (Group B) VMT release.
Main Results:
- Ocriplasmin caused temporary impairment in visual acuity and retinal sensitivity at 1 week, followed by significant improvement by 3 months.
- Eyes without VMT release (Group B) showed greater initial impairment.
- VMT release (Group A) correlated with better functional recovery and improved fixation stability.
Conclusions:
- Microperimetry confirms early, reversible functional impairment post-ocriplasmin injection.
- Functional recovery is more favorable in patients achieving VMT release.
